Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
6.43
+0.01 (0.16%)
Oct 14, 2026, 9:55 AM EDT - Market open
Lifecore Biomedical Revenue
Lifecore Biomedical had revenue of $34.17M in the quarter ending June 30, 2026, a decrease of -6.25%. This brings the company's revenue in the last twelve months to $128.96M, up 0.07% year-over-year. In the fiscal year ending May 25, 2025, Lifecore Biomedical had annual revenue of $128.87M with 0.47% growth. That makes Lifecore Biomedical the 20,681st largest company in the world by revenue and 3,135th in the United States.
Revenue (ttm)
$128.96M
Revenue Growth
+0.07%
P/S Ratio
1.88
Revenue / Employee
$338,913
Employees
382
Market Cap
243.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 25, 2025 | 128.87M | 606.00K | 0.47% |
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | 160.07M | -397.49M | -71.29% |
| May 26, 2019 | 557.56M | 33.33M | 6.36% |
| May 27, 2018 | 524.23M | 54.45M | 11.59% |
| May 28, 2017 | 469.78M | -7.14M | -1.50% |
| May 29, 2016 | 476.92M | -62.34M | -11.56% |
| May 31, 2015 | 539.26M | 62.44M | 13.10% |
| May 25, 2014 | 476.81M | 35.11M | 7.95% |
| May 26, 2013 | 441.71M | 124.16M | 39.10% |
| May 27, 2012 | 317.55M | 40.82M | 14.75% |
| May 29, 2011 | 276.73M | 44.64M | 19.23% |
| May 30, 2010 | 232.09M | 3.54M | 1.55% |
| May 31, 2009 | 228.55M | -2.64M | -1.14% |
| May 25, 2008 | 231.19M | 25.76M | 12.54% |
| May 27, 2007 | 205.43M | -23.70M | -10.34% |
| May 28, 2006 | 229.13M | 24.41M | 11.92% |
| May 29, 2005 | 204.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 770.20M |
| Organogenesis Holdings | 457.45M |
| Aurora Cannabis | 221.16M |
| Akebia Therapeutics | 219.06M |
| Canopy Growth | 206.77M |
| Glass House Brands | 176.98M |
| Anika Therapeutics | 120.65M |
| ADC Therapeutics | 79.58M |
LFCR News
- 6 days ago - Lifecore Biomedical to Participate at Upcoming Industry Conferences - GlobeNewsWire
- 8 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD) - GlobeNewsWire
- 13 days ago - Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholders - GlobeNewsWire
- 13 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ) - GlobeNewsWire
- 14 days ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lifecore Biomedical, Inc. (LFCR) - Newsfile Corp
- 15 days ago - Lifecore downgraded to Market Perform from Outperform at Barrington - TheFly
- 15 days ago - Lifecore downgraded to Hold from Buy at Craig-Hallum - TheFly
- 15 days ago - Lifecore downgraded to Market Perform from Outperform at William Blair - TheFly